IL-17a reverts the reduction in CD8+ T cell response generated by anti-CD20 treatment.

FIOCCA VERNENGO F; BECCARIA CG; ALMADA L; ARAUJO FURLÁN CL; TOSELLO BOARI J; GOROSITO SERRÁN M; GAZZONI Y; MONTES CL; ACOSTA RODRIGUEZ EV; GRUPPI A

Congreso; SAIC-SAI-SAFIS 2018.; 2018

Anti-CD20 therapy, that depletes B cells, is widely usedto treat autoimmunity and lymphomas. B cells can regulateT cell responses because they have antibody independentfunctions, such as antigen presentation andcytokine secretion. To evaluate the effect of anti-CD20treatment on CD8+T cell response we used the experimentalmodel of Trypanosoma cruzi infection, sinceCD8+T cells are essential for infection control.For that, anti-CD20 mAb was injected eight days beforeinfection with 5000 trypomastigotes, to deplete B cellsand CD8+T cell response was analyzed at different dayspost infection (dpi). Infected control mice were injectedwith an isotype antibody.At 20 dpi, B-cell depleted mice (BcD) exhibited higherparasitism (determined by parasite DNA quantificationby RT-PCR) in the spleen, liver and heart than controls(p